Intracellular Zn2+ levels regulate susceptibility to hepatitis B virus infection by modulating NTCP-mediated viral entry

Yumi Itoh, Chiharu Morita, Cui Jinzi, Tatsuya Suzuki, Aiko Ono, Tomomi Hishinuma, Kento Fukano, Daisuke Okuzaki, Daisuke Motooka, Kei Miyakawa, Yasuyoshi Hatayama, Akihide Ryo, Mitsuyoshi Suzuki, Hajime Takei, Hiroshi Nittono, Tomohisa Tanaka, Koichi Watashi, Masamichi Muramatsu, Kohji Moriishi, Yoshiharu Matsuura, Toru Okamoto

doi:10.1016/j.antiviral.2026.106542

CrossrefKarta ta’ informazzjoni

Intracellular Zn2+ levels regulate susceptibility to hepatitis B virus infection by modulating NTCP-mediated viral entry

Yumi Itoh, Chiharu Morita, Cui Jinzi, Tatsuya Suzuki, Aiko Ono, Tomomi Hishinuma, Kento Fukano, Daisuke Okuzaki, Daisuke Motooka, Kei Miyakawa, Yasuyoshi Hatayama, Akihide Ryo, Mitsuyoshi Suzuki, Hajime Takei, Hiroshi Nittono, Tomohisa Tanaka, Koichi Watashi, Masamichi Muramatsu, Kohji Moriishi, Yoshiharu Matsuura, Toru Okamoto

Antiviral Research · 2026-11 · 255 · 106542

DOI: 10.1016/j.antiviral.2026.106542 ↗

Astratt Dettalji biblijografiċi

Astratt

Ebda abstract disponibbli.

Dettalji biblijografiċi

Awturi/Awturiċi: Yumi Itoh, Chiharu Morita, Cui Jinzi, Tatsuya Suzuki, Aiko Ono, Tomomi Hishinuma, Kento Fukano, Daisuke Okuzaki, Daisuke Motooka, Kei Miyakawa, Yasuyoshi Hatayama, Akihide Ryo, Mitsuyoshi Suzuki, Hajime Takei, Hiroshi Nittono, Tomohisa Tanaka, Koichi Watashi, Masamichi Muramatsu, Kohji Moriishi, Yoshiharu Matsuura, Toru Okamoto
Ġurnal: Antiviral Research
Sena tal-pubblikazzjoni: 2026
Volum / Ħarġa: 255
Paġni: 106542
Pubblikatur: Elsevier BV
DOI: 10.1016/j.antiviral.2026.106542
ISSN: 0166-3542
Sors: Crossref

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.